NASDAQ · RLYB
Healthcare · Biotechnology
$16.77
Down-$0.23 (-1.35%)
Updated Aug 19, 2026, 10:37 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
RLYB closed at $16.77 after 21 trading sessions, down 0.83% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $16.87 | $17.135 | $16.73 | $16.77 | 10.26K |
| Aug 17, 2026 | $17.00 | $17.29 | $16.66 | $17.00 | 17.13K |
| Aug 14, 2026 | $17.01 | $17.23 | $16.67 | $16.99 | 12.92K |
| Aug 13, 2026 | $16.75 | $17.35 | $16.75 | $16.96 | 74.31K |
| Aug 12, 2026 | $16.39 | $16.80 | $16.33 | $16.59 | 17.67K |
| Aug 11, 2026 | $16.81 | $16.81 | $16.34 | $16.38 | 8.78K |
| Aug 10, 2026 | $16.25 | $16.98 | $16.23 | $16.61 | 23.32K |
| Aug 7, 2026 | $16.1135 | $16.51 | $16.02 | $16.16 | 12.3K |
| Aug 6, 2026 | $16.28 | $16.65 | $15.95 | $16.19 | 27.12K |
| Aug 5, 2026 | $16.10 | $16.26 | $15.97 | $16.14 | 34.35K |
| Aug 4, 2026 | $15.91 | $16.1301 | $15.85 | $15.96 | 44.9K |
| Aug 3, 2026 | $16.23 | $16.23 | $15.8801 | $15.95 | 19.6K |
| Jul 31, 2026 | $15.91 | $16.06 | $15.86 | $15.93 | 18.1K |
| Jul 30, 2026 | $15.91 | $16.28 | $15.90 | $16.07 | 12.05K |
| Jul 29, 2026 | $16.20 | $16.20 | $15.945 | $15.96 | 16.37K |
| Jul 28, 2026 | $16.185 | $16.27 | $15.90 | $16.155 | 25.32K |
| Jul 27, 2026 | $16.47 | $16.48 | $16.06 | $16.31 | 16.07K |
| Jul 24, 2026 | $16.46 | $16.64 | $16.00 | $16.31 | 41.59K |
| Jul 23, 2026 | $16.47 | $16.98 | $16.39 | $16.39 | 30.49K |
| Jul 22, 2026 | $16.93 | $16.93 | $16.49 | $16.62 | 35.45K |
| Jul 21, 2026 | $16.74 | $16.96 | $16.27 | $16.91 | 25.75K |
The latest Smart Investors Daily articles mentioning RLYB.
RLYB research
Company profile and research snapshot.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 15, 2025 | Jones Trading | Hold | — |
| Apr 9, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 17, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 12, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 13, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Finnhub · May 4, 2026
Rallybio Corp: Rallybio Corp - Candid terminates merger agreement with Rallybio on May 3, 2026 - SEC filing Rallybio Corp - entitled to $50 million parent termination fee - SEC filing Rallybio...
Benzinga · May 4, 2026
ChartMill · Mar 30, 2026
Rallybio Corp (RLYB) exemplifies a high-growth momentum stock in a strong technical uptrend, meeting key Minervini Trend Template criteria with accelerating earnings.
SeekingAlpha · Mar 2, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RLYB.
